Open Access在丹麦启用利拉鲁肽治疗的患者的临床特征以及降糖药物使用情况:一项常规临床治疗处方研究
Author(s) -
Knudsen Jakob S.,
Thomsen Reimar W.,
Pottegård Anton,
Knop Filip K.,
Sørensen Henrik T.
Publication year - 2019
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12919
Subject(s) - liraglutide , medicine , medical prescription , drug , diabetes mellitus , intensive care medicine , emergency medicine , pharmacology , type 2 diabetes , endocrinology
Highlights This population‐based real‐world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1‐5 trials that led to liraglutide registration, underscoring the need for further post‐marketing studies.